安捷伦Q3 FY2026营收$18.8亿超预期、EPS $1.62超预期$0.13，全年指引上调，盘后涨3.2%至52周高位附近

Nvidia Q2 revenue more than doubles, CEO Huang says AI at its ’inflection point’
Introduction & Market Context
Agilent Technologies (NYSE:A) presented fiscal third-quarter 2026 results on August 26, 2026, showcasing stronger-than-expected performance across revenue, margins, and earnings. The life sciences and diagnostics equipment maker reported revenue of $1.88 billion with core growth of 7.3%, beating the high end of guidance by 140 basis points, while operating margins expanded 320 basis points year-over-year to 28.3%.
The company’s shares rose 3.17% in after-hours trading to $160, approaching the 52-week high of $160.51, after closing the regular session at $155.08. The positive market reaction reflected investor confidence in Agilent’s execution and the company’s decision to raise full-year guidance across revenue, margins, and earnings per share.
Quarterly Performance Highlights
Agilent’s third-quarter results demonstrated broad-based strength across its business portfolio. The company reported adjusted earnings per share of $1.62, up 18% year-over-year, on revenue that grew 8.1% on a reported basis. The presentation highlighted several key performance drivers, including high-single-digit instrument growth and nearly 30% expansion in the company’s specialty CDMO (contract development and manufacturing organization) business.
The following chart illustrates the comprehensive financial performance for the quarter:
Operating margin performance significantly exceeded expectations, coming in at 28.3% compared to guidance, representing an improvement of 190 basis points quarter-over-quarter. Management attributed this margin expansion to volume leverage and what the company calls "compounding Ignite efficiencies"—referring to its operational excellence program. The presentation noted that results included a 110 basis point net benefit from tariff refunds in the quarter, though even excluding this benefit, margins expanded substantially.
Capital allocation during the quarter reflected Agilent’s balanced approach to returning value to shareholders while investing in growth. The company generated $519 million in operating cash flow, deployed $78 million to repurchase 0.61 million shares, invested $80 million in capital expenditures, and returned $72 million to shareholders through dividends.
Business Segment Performance
The presentation emphasized how Agilent’s Ignite Operating System is driving value across all three business segments, each delivering solid growth with healthy margins.
The Life Sciences and Diagnostics Markets Group (LDG) led performance with 10% core growth and a 23.5% operating margin. The segment benefited from low double-digit liquid chromatography (LC) growth against a mid-teens comparison from the prior year, along with the nearly 30% surge in the Advanced Therapeutics Division, which serves the rapidly growing biologics and cell and gene therapy markets.
The Applied Markets Group (AMG) posted 7% core growth with a 24.9% operating margin, supported by strong demand in semiconductor-related workflows. The segment also saw more than 20% growth in PFAS (per- and polyfluoroalkyl substances) testing, reflecting increased regulatory scrutiny and environmental monitoring requirements.
The Agilent CrossLab Group (ACG), which provides consumables and services, delivered 5% core growth with the highest operating margin of 34.3%. The segment reported strong consumables growth, improving trends in China, and mid-single-digit services growth in line with expectations.
The segment-by-segment breakdown is illustrated below:
Geographic Performance Analysis
Agilent’s geographic performance revealed strength in the Americas and Asia-Pacific regions, with more modest growth in Europe. The presentation characterized the results as "broad-based growth" across key markets.
The Americas region delivered the strongest performance with 10% core growth, representing 40% of total Agilent revenue. Asia-Pacific, including China, posted 9% core growth and accounted for 33% of revenue. Europe showed 2% core growth, contributing 27% of total revenue, reflecting the more challenging macroeconomic environment in that region.
The geographic revenue breakdown is shown in the following illustration:
The strong performance in China, which grew 9% in the quarter according to management commentary, represented a notable improvement in what had been a challenging market for life sciences companies. The presentation suggested that local customer relationships, localized manufacturing capabilities, and a stronger demand pipeline contributed to the momentum.
Revenue Mix & Business Model Strength
Agilent’s business model continues to demonstrate resilience through its balanced revenue mix between instruments and recurring revenue streams. The presentation highlighted that consumables, services, and informatics collectively account for 66% of total revenue, with instruments representing the remaining 34%.
The following chart illustrates the company’s revenue composition:
A particularly encouraging indicator of sustained demand was the company’s disclosure that book-to-bill ratios have remained at or above 1.0x for the tenth consecutive quarter. This metric, which compares new orders to revenue recognized, suggests that the order pipeline remains healthy and supports continued growth momentum.
The high proportion of recurring revenue provides Agilent with greater visibility and stability, as consumables and service contracts tied to its large installed base of instruments generate predictable cash flows. This business model characteristic becomes particularly valuable during periods of economic uncertainty or when instrument purchasing decisions may be delayed.
End Market Performance
The presentation provided detailed insight into performance across Agilent’s diverse end markets, revealing strength in pharmaceutical and applied markets offset by weakness in academia and government funding.
The pharmaceutical market, representing 38% of Agilent’s revenue, delivered the strongest growth at 12%. The presentation attributed this to biotech momentum, robust contributions from GLP-1 (glucagon-like peptide-1) drug development workflows, and the previously mentioned nearly 30% growth in the Advanced Therapeutics Division. This performance reflects the ongoing innovation in drug development, particularly in biologics, cell and gene therapies, and the rapidly expanding obesity and diabetes treatment markets.
Diagnostics and clinical markets grew 6%, driven by companion diagnostics demand and genomics growth, with pathology orders up double-digits. The chemicals and advanced materials segment posted 7% growth, led by advanced materials demand tied to robust semiconductor industry activity. Environmental and forensics markets grew 5%, with continued strength in PFAS testing momentum.
The detailed end market performance breakdown is presented below:
Two markets showed more challenging conditions. Academia and government declined 3%, reflecting what the presentation described as a "muted but stabilizing research funding environment," though the company noted low single-digit growth excluding China. The food market was flat year-over-year, though management indicated this exceeded expectations against a tough comparison, with strong performance in China.
Forward Guidance & Outlook
Reflecting increased confidence in business performance, Agilent raised its full-year fiscal 2026 guidance across multiple metrics. The updated outlook demonstrates management’s conviction that the momentum demonstrated in the third quarter will continue.
For the full fiscal year 2026, the company now expects net revenue between $7.49 billion and $7.51 billion, representing an increase of $60 million at the midpoint versus prior guidance. Core revenue growth is projected at 5.8% to 6.0%, up 65 basis points at the midpoint from the previous forecast. Operating margin expansion is now expected to exceed 130 basis points year-over-year, an improvement of more than 45 basis points versus prior guidance. Adjusted earnings per share guidance increased to $6.18 to $6.21, up $0.15 at the midpoint.
The updated full-year guidance is illustrated below:
Additional financial metrics for fiscal 2026 include expected operating cash flow of $1.6 billion to $1.7 billion, capital expenditures of $450 million, and dividends of $290 million. The company plans to continue anti-dilutive share repurchases at a minimum, with a diluted share count of approximately 283 million shares.
For the fourth quarter of fiscal 2026, Agilent provided guidance for net revenue of $1.98 billion to $2.00 billion, representing core growth of 5.2% to 6.2%. Adjusted earnings per share are expected to range from $1.71 to $1.74. The company noted that fourth-quarter guidance reflects healthy demand trends across its largest end markets and expects year-to-date momentum to continue.
The fourth-quarter outlook is detailed in the following chart:
Strategic Drivers & Operational Excellence
Throughout the presentation, Agilent emphasized the role of its Ignite Operating System in driving compounding operational efficiencies. The company highlighted several specific accomplishments, including pricing contributions of approximately 200 basis points in the quarter—exceeding the original full-year target of more than 100 basis points.
The presentation pointed to several longer-term growth drivers supporting the company’s outlook. These include continued strength in pharmaceutical and biotech markets, the rebound in China, new product launches gaining traction, instrument replacement cycles in liquid and gas chromatography, and emerging reshoring demand from large pharmaceutical customers.
Management commentary referenced in related earnings coverage indicated that Agilent secured reshoring orders from five of the top 10 global drugmakers in the third quarter alone. The company estimates the reshoring opportunity at approximately $1 billion through 2030 and expects to capture at least one-third of that addressable market, with revenue expected to build meaningfully in 2027 and beyond.
The strong third-quarter results and raised guidance underscore Agilent’s positioning in attractive end markets experiencing secular growth tailwinds, from advanced therapeutics and precision medicine to semiconductor manufacturing and environmental testing. The company’s operational discipline, reflected in margin expansion that outpaced revenue growth, demonstrates management’s ability to translate top-line momentum into enhanced profitability. With the stock trading near 52-week highs following the presentation, investors appear to have confidence in Agilent’s ability to sustain this performance trajectory through the remainder of fiscal 2026 and beyond.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.